InvestorsHub Logo
Followers 86
Posts 12714
Boards Moderated 0
Alias Born 10/12/2010

Re: biopharm post# 170659

Tuesday, 07/29/2014 7:45:08 PM

Tuesday, July 29, 2014 7:45:08 PM

Post# of 345659

1) July 22, 2009 ...BMS en route to scooping up Medarex ..... but not everyone was happy with that deal....



... but I'm sure BMS did not care that much, they got Adnexus for less than many investors thought they should have sold to BMS for-- and who was part of this deal? John Edwards

John Edwards has 30 years of experience in discovery, development, and global commercialization of biopharmaceuticals, involving over 10 FDA approved biologics at four successful biotechnology companies. Most recently John helped lead Adnexus from a start-up to the $450M acquisition by BMS within 4 years, where he then continued with the company for next 3 years serving as President.

www.f-star.com/about-board-john-edwards.php



... and what does F-Star, Pall Life Sciences and Peregrine Pharmaceuticals all have in common?

They are the sole 3 corporate sponsors at the 9th Annual Immunotherapies and Vaccine "ImVacs"--- and Peregrine Pharmauceuticals is now listed as one of the 3 (listed on page #2)

http://www.giievent.kr/chi296982-2014/catalog.pdf

-------------------------------------------

interesting that F-star guest speaker not listed just yet...and other than Peregrines Jeff H. presentation-- there is Omid Hamid that will be speaking about immunotherapy combo's for melanoma... hmmmm

"Bavituximab is a first-in-class phosphatidylserine (PS)-targeting monoclonal antibody that is the cornerstone of a broad clinical
pipeline."
-- Big Pharmas nightmare... unless they are fortunate enough to have The Bavi Edge!

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent CDMO News